Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procrit Sales Slump Continues Due To 10% Year-Over-Year Price Decline

This article was originally published in The Pink Sheet Daily

Executive Summary

Conditions, however, are more favorable than in previous quarters due to a June price increase on the EPO brand, J&J says. With prices locked into 12-month contracts, it may take awhile for J&J to reap the full benefit of the price increase.

You may also be interested in...



J&J Expects Procrit Stability Under Medicare Average Sales Price Model

Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.

J&J Expects Procrit Stability Under Medicare Average Sales Price Model

Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.

Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says

The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel